Lung metastasis following temporary discontinuation of lenvatinib and tislelizumab in hepatocellular carcinoma:A case report  

作　　者：Chen-Dong Wang Run-Dong Liu Ming-Jie Liu Jia Song 

机构地区：[1]Hepatic Surgery Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei Province,China [2]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei Province,China [3]Department of Oncology,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430062,Hubei Province,China

出　　处：《World Journal of Gastrointestinal Surgery》2025年第3期391-397,共7页世界胃肠外科杂志(英文)

摘　　要：BACKGROUND Hepatocellular carcinoma(HCC)is a prevalent malignancy in China,primarily diagnosed at advanced stages,which limits treatment options and increases mortality rates.Conversion therapy,which includes systemic and locoregional treatments,aims to render unresectable tumors resectable.Nonetheless,research is scant on the risks of disease progression during the temporary cessation of targeted drugs and immune checkpoint inhibitors before surgery.CASE SUMMARY This report describes a 58-year-old male with HCC who developed lung meta-stases following the discontinuation of lenvatinib and tislelizumab,revealing the necessity for further investigation into the management of HCC patients during the perioperative period,particularly concerning the timing and duration of tar-geted therapy and immunotherapy.CONCLUSION Our study highlights the complex challenges in managing advanced HCC and emphasizes the critical need for ongoing research to refine treatment strategies and improve patient outcomes.

关 键 词：Hepatocellular carcinoma Hepatic arterial infusion chemotherapy Lenvatinib Tislelizumab Conversion therapy Case report 

分 类 号：R73[医药卫生—肿瘤]